Theriva Biologics Inc.

10/16/2024 | Press release | Distributed by Public on 10/16/2024 14:32

Theriva Biologics anuncia la designación de medicamento huérfano concedida por la Comisión Europea al VCN-01 para el tratamiento del retinoblastoma

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.